Inhaled Colistin for Treatment of Pneumonia due to Colistin-Only-Susceptible *Acinetobacter baumannii*

Hee Kyoung Choi,¹ Young Keun Kim,¹ Hyo Youl Kim,¹ and Young Uh²

Departments of ¹Internal Medicine and ²Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

**Purpose:** Colistin is used for the treatment of pneumonia associated with multi-drug-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. However, the best route of administration and dosage is not known. We report our experience with aerosolized colistin in twelve patients with pneumonia caused by colistin-only-susceptible (COS) *A. baumannii*. **Materials and Methods:** We retrospectively reviewed patients’ medical records who were treated with aerosolized colistin for the treatment of pneumonia. **Results:** Ten patients were treated only with aerosolized colistin inhalation and two patients received a 3-day course intravenous colistin, and then switched to colistin inhalation therapy. The median duration of aerosolized colistin therapy was 17 days (5-31 days). Four patients were treated only with aerosolized colistin, whereas 4 patients received concomitant glycopeptides, and 4 received concomitant levofloxacin or cefoperazone/sulbactam. At the end of the therapy, the clinical response rate and bacteriological clearance rate was 83% and 50%, respectively. Colistin-resistant strains were isolated from 3 patients after aerosolized colistin therapy; however, all of them showed favorable clinical response. The median interval between inhalation therapy and resistance was 7 days (range 5-19 days). Acute kidney injury developed in 3 patients. Two patients experienced *Clostridium difficile* associated diarrhea. One patient developed fever and skin rash after aerosolized colistin therapy. No patient developed neurotoxicity or bronchospasm. **Conclusion:** Colistin inhalation therapy is deemed tolerable and safe, and could be beneficial as an adjunctive therapy for the management of pneumonia due to COS *A. baumannii*. However, the potential development of colistin resistance cannot be overlooked.

**Key Words:** *Acinetobacter baumannii*, colistin, pneumonia

---

**INTRODUCTION**

The growing epidemic of multidrug-resistant (MDR) gram-negative bacteria has led clinicians to prescribe colistin. However, due to inadequate penetration in the lung parenchyma, the effectiveness of intravenous (IV) colistin therapy for pneumonia has been questioned.¹

Although inhaled colistin has been used successfully to prevent and cure pulmonary infections in patients with cystic fibrosis colonized with *Pseudomonas aeru-
Inhaled Colistin Therapy for A. baumannii Pneumonia

ginos.a; there is limited data supporting effectiveness and tolerability of inhaled colistin therapy in non-cystic fibrosis patients with pneumonia due to MDR A. baumannii. We report here our experience with critically ill patients who received colistin inhalation therapy for the treatment of colistin-only-susceptible (COS) A. baumannii pneumonia.

MATERIALS AND METHODS

Study design
A retrospective review of medical records of patients who received inhaled colistin therapy for >72 h was performed at a tertiary care university hospital in Wonju, Korea. A pharmacy-generated list identified patients aged ≥18 years who received inhaled colistin therapy from March 2012 through September 2012. Colistin methanesulfonate was used in all patients. The daily dosage of nebulized colistin was 150 mg divided into 2 doses, and 75 mg of colistin was diluted in 4 mL of sterile normal saline. The solution was nebulized through a conventional nebulizer. Patients demographic characteristics, underlying diseases, Acute Physiologic and Chronic Health Evaluation (APACHE) II scores on the first day of colistin inhalation therapy, concomitant use of antibiotics, and nephrotoxicity were reviewed. The study was approved by the Institutional Review Board (YWMR-12-5-042) of Yonsei University Severance Hospital.

Microbiological testing
All causative micro-organisms were identified using conventional microbiological methods. Identification and susceptibility tests were done using the Vitek 2 system (BioMérieux, Marcy l’Étoile, France) and MicroScan WalkAway System (Siemens Healthcare Diagnostics, Sacramento, CA, USA). Antimicrobial susceptibilities of all isolates were interpreted by the Clinical and Laboratory Standards Institute recommended interpretive guidelines. Susceptibility to colistin was tested using broth microdilution method. An isolate was defined as COS if it was resistant to all anti-pseudomonal agents except colistin.

Definitions
Pneumonia was diagnosed on the basis of a radiographic finding of a new and progressive pulmonary infiltrate and at least 2 of the following clinical criteria: body temperature, >38°C or <35.5°C; leukocytosis (leukocyte count, >12000 cells/mm³); and clinical evidence of suggestive of pneumonia such as purulent bronchial secretions and a decrease in oxygenation. The etiology of the pneumonia was established by isolation of the organism from endotracheal aspirates or bronchoalveolar lavage with a concentration of ≥10⁶ CFU/mL.

Clinical outcome was classified as clinical cure (i.e. resolution of presenting symptoms and signs of infection by the end of colistin treatment), improvement (i.e. partial resolution of presenting symptoms and signs of infection), failure (i.e. persistence or worsening of presenting symptoms and/or signs of infection during colistin administration), and recurrence of infection (i.e. occurrence of a new episode of infection at least 72 h after clinical resolution of a preceding episode). Favorable clinical response was defined as clinical cure or clinical improvement. Microbiological outcome was rated as eradication of the pathogen (i.e. no growth of the pathogen in the final culture of specimens during the entire hospitalization), persistence of the pathogen (i.e. persistent growth of the responsible pathogen regardless of the clinical outcome of the infection), recurrence (re-growth) of the pathogen (i.e. re-isolation of the same pathogen regardless of the clinical outcome of the infection), or colonization (i.e. persistence or reemergence of the pathogen without symptoms and signs of infection).

Pneumonia-related mortality was defined as death that occurred during the treatment period when the signs of pneumonia remained.

Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE) criteria were used to evaluate the nephrotoxicity of colistin. Glomerular filtration rate was calculated by the Modification of Diet in the Renal Disease Study equation: 175×(serum creatinine)^1.154×(age)^0.203×(0.742 if female). We reviewed information on patients’ creatinine level until their hospital discharge.

All adverse effects related to colistin use, such as bronchospasm, neurotoxicity, hypersensitivity reactions (including rash, pruritus, urticaria and fever) were also recorded.

RESULTS

During the study period, 12 (7 males) patients were treated with inhaled colistin for COS A. baumannii pneumonia. Table 1 describes the demographic and clinical features of these patients. The median age of the patients was 75 years, and median APACHE II score on the day of inhaled colistin treatment was 19.5 (range 12-29). Polybacterial infections were observed in 5 patients. In 2 of these 5 patients (Case 9 and
| Case | Sex | Age, yrs | Prior use of IV colistin, days | Duration of aerosolized colistin, days | Underlying diseases | Isolated pathogen | Location | Concomitant bacteremia | Tracheostomy | Prior use of antibiotics within 72 h | Concomitant antibiotics | APACHE II score | BUN, mg/dL | Cr, mg/dL | GFR, mL/min/1.73 m² | Alb, g/dL |
|------|-----|----------|-------------------------------|---------------------------------------|---------------------|------------------|----------|----------------------|-------------|------------------------|------------------------|----------------|----------|--------|--------------------------|--------|
| 1    | F   | 73       | 4                             | 17                                    | Neurovascular disease | A. baumannii     | ICU      | No                   | Yes         | Cefoperazone/sulbactam, oral vancomycin | -                     | 23               | 19       | 0.62   | 100.6                    | 2.4    |
| 2    | M   | 78       | 0                             | 31                                    | ESRD, neurovascular disease | A. baumannii     | Ward    | No                   | No          | Meropenem, rifampicin              | -                     | 27               | 126      | 6.27   | 9.2                      | 2.4    |
| 3    | F   | 77       | 3                             | 24                                    | CKD, neurovascular disease | A. baumannii     | ICU      | Yes                  | Yes         | Meropenem, teicoplanin              | Teicoplanin, vancomycin, cefoperazone/sulbactam | 25   | 33        | 2.86 | 16.9       | 3.1                    |
| 4    | F   | 75       | 0                             | 9                                     | Neurovascular disease | A. baumannii, MRSA | ICU      | No                   | Yes         | Ceftazidime, vancomycin              | Vancomycin             | 17               | 22       | 0.21   | 347.6                    | 2.8    |
| 5    | M   | 75       | 0                             | 14                                    | CHF, neurovascular disease | A. baumannii     | ICU      | No                   | No          | Meropenem, vancomycin              | -                     | 29               | 45       | 1.54   | 47                      | 2.4    |
| 6    | M   | 81       | 0                             | 26                                    | COPD                | A. baumannii     | ICU      | No                   | Yes         | Imipenem/cilastatin, vancomycin      | Levofoxacin            | 20               | 34       | 1.83   | 37.9                    | 2.9    |
| 7    | F   | 73       | 0                             | 5                                     | DM, CHF, neurovascular disease | A. baumannii     | Ward    | No                   | Yes         | Ceftazidime, vancomycin              | -                     | 12               | 60       | 1.45   | 37.6                    | 3.2    |
| 8    | M   | 62       | 0                             | 17                                    | Malignancy, COPD, neurovascular disease | A. baumannii, MRSA | ICU      | No                   | Yes         | Imipenem/cilastatin, teicoplanin, metronidazole | Teicoplanin, metronidazole | 19   | 30        | 0.77 | 109.1                  | 2.8    |
| 9    | M   | 78       | 0                             | 23                                    | DM, CHF, CKD, neurovascular disease | A. baumannii, P. aeruginosa | ICU      | No                   | Yes         | Imipenem/cilastatin                 | TMP/SMX, rifampicin   | 27               | 45       | 1.63   | 43.7                    | 3      |
| 10   | M   | 75       | 0                             | 15                                    | CHF, CKD            | A. baumannii     | ICU      | No                   | No          | Imipenem/cilastatin, teicoplanin     | Cefoperazone/sulbactam | 13               | 45       | 1.97   | 35.3                    | 2.8    |
| 11   | M   | 47       | 0                             | 21                                    | DM, neurovascular disease, alcoholic LC | A. baumannii, P. aeruginosa | ICU      | No                   | No          | Meropenem, vancomycin              | Cefoperazone/sulbactam | 15   | 20        | 0.93 | 92.3                    | 3.9    |
| 12   | F   | 75       | 0                             | 15                                    | DM, neurovascular disease | A. baumannii, MRSA | ICU      | No                   | No          | Imipenem/cilastatin                 | Vancomycin             | 15               | 12       | 0.33   | 206.3                   | 2.8    |

F, female; ICU, intensive care unit; M, male; ESRD, end-stage renal disease; CKD, chronic renal disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; LC, liver cirrhosis; MRSA, methicillin-resistant *Staphylococcus aureus*; APACHE, acute physiologic and chronic health evaluation; BUN, serum blood urea nitrogen; Cr, serum creatinine; GFR, glomerular filtration rate; Alb, serum albumin; TMP/SMX, trimethoprim-sulfamethoxazole.
Inhaled Colistin Therapy for *A. baumannii* Pneumonia

11), *P. aeruginosa* was isolated from the same culture specimen. Methicillin resistant *Staphylococcus aureus* was isolated in the other 3 patients (Case 4, 8, 12). All patients were spontaneously breathing without mechanical ventilation. However, most patients were severely ill (10 were in intensive care unit), and had many underlying diseases. One patient (Case 3) had concomitant COS *A. baumannii* bacteraemia. She received IV colistin for 3 days, and then switched to colistin inhalation with IV cefoperazone/sulbactam therapy. Because inhaled colistin was administered as definitive therapy in all patients, inhalation treatment started 3-5 days after symptom onset. Therefore, all patients had received other broad spectrum antibiotics before colistin inhalation therapy. Inhaled colistin monotherapy was administered to 4 patients (Case 1, 2, 5, and 7). In 5 patients, an additional antimicrobial agent with activity against gram-negative bacteria was given during the course of inhaled colistin treatment.

Favorable clinical response (cure or improvement) was observed in 10 of the 12 patients (Table 2). Follow-up cultures were available for all patients and *A. baumannii* was eradicated in 6 patients. The all-cause in-hospital mortality was 33.3% (4/12 patients). Pneumonia-associated mortality was 8.3% (1/12 patients). One patient died from subsequent clinical sepsis related to severe *Clostridium difficile* infection, by 47 days after resolving from pneumonia episode (Case 9). In addition, other 2 patients died from acute bleeding and myocardial infarction. Since *A. baumannii* isolates in our case series were resistant to other antimicrobials, we expected that the clinical outcomes could be attributed to

### Table 2. Treatment Outcomes of Inhaled Colistin Therapy

| Case | Clinical outcomes | Microbiologic outcomes | Length of hospital stay, days |
|------|-------------------|------------------------|-------------------------------|
| 1    | Cure              | Recurrence             | 375                           |
| 2    | Improvement       | Eradication            | 372                           |
| 3    | Improvement       | Eradication            | 290                           |
| 4    | Improvement       | Persistent             | 99                            |
| 5    | Failure           | Eradication            | Yes                           |
| 6    | Cure              | Eradication            | 117                           |
| 7    | Failure           | Persistent             | Yes                           |
| 8    | Improvement       | Persistent             | Sepsis, severe CDAD 507       |
| 9    | Cure              | Persistent             | Acute myocardial infarction 112|
| 10   | Improvement       | Eradication            | 301                           |
| 11   | Cure              | Eradication            | 102                           |
| 12   | Cure              | Colonization           | 102                           |

CDAD, *Clostridium difficile* associated diarrhea.

### Table 3. Adverse Events during Colistin Inhalation Therapy

| Case | Nephrotoxicity, RIFLE | Hypersensitivity | Others | Superinfection | Colistin resistant *A. baumannii* | Time between colistin inhalation and development of resistance, days |
|------|-----------------------|------------------|--------|----------------|-------------------------------|----------------------------------------------------------|
| 1    | None                  |                  |        | MRSA           |                               | 5                                                       |
| 2    | -                     | CDAD             |        | Yes            | MRSA                          | 0                                                       |
| 3    | None                  |                  |        | Yes            | MRSA                          | 5                                                       |
| 4    | R                     |                  |        | Yes            | MRSA                          | 0                                                       |
| 5    | R                     |                  |        | Yes            | MRSA                          | 0                                                       |
| 6    | None                  |                  |        |                 |                               | 19                                                      |
| 7    | None                  | Yes, fever & skin rash | MRSA |                 |                               | 19                                                      |
| 8    | None                  |                  |        |                 |                               | 19                                                      |
| 9    | None                  | CDAD             |        | Yes            |                               | 19                                                      |
| 10   | None                  |                  |        | MRSA           |                               | 19                                                      |
| 11   | None                  |                  |        |                 |                               | 19                                                      |
| 12   | I                     |                  |        |                 |                               | 19                                                      |

RIFLE, risk, injury, failure, loss, and end-stage kidney disease; CDAD, *Clostridium difficile* associated diarrhea; MRSA, methicillin-resistant *Staphylococcus aureus*.
nebulized colistin rather than systemic antimicrobial agents. However, the outcomes were different from our expectations. Among the 4 patients treated with colistin inhalation therapy alone, favorable clinical response was observed in 2 (50%) patients. Two of the 4 patients died during the hospitalization and one patient died from pneumonia. By contrast, all the 8 patients who received concurrent systemic antimicrobial agents showed favorable outcome, and only one died from acute myocardial infarction.

Colistin inhalation therapy was well tolerated (Table 3). During treatment, no patient experienced bronchospasm or neurotoxicity. Only one patient experienced fever and skin rash after colistin inhalation therapy (Case 7). The physician suspected colistin hypersensitivity and changed her antibiotic regimen. Two patients experienced Clostridium difficile associated diarrhea. Three patients suffered from acute kidney injury: 2 RIFLE-R, and one RIFLE-I. Among them, 2 patient’s peak serum creatinine levels were within normal reference range (Case 4 and 12) and renal functions returned to baseline at the time of hospital discharge. One patient (Case 5) died and follow up of the creatinine level was not possible for this patient. None of the patients discontinued colistin treatment or required renal replacement therapy because of colistin induced nephrotoxicity. Colistin resistance in subsequent sputum culture isolates developed in 3 patients. Median interval between colistin inhalation therapy and resistance was 7 days (range 5-19 days). One patient (Case 4) received colistin inhalation therapy based on the result of culture study performed 5 days prior to the treatment. Subsequent sputum culture obtained on the treatment initiation day was reported as a colistin resistant A. baumannii thereafter. Despite colistin resistance, colistin inhalation therapy was continued and clinical outcomes were favorable in all of 4 patients. Burkholderia cepacia superinfection was observed in one patient (Case 8).

DISCUSSION

Colistin has a narrow spectrum of use and is primarily used for infections with P. aeruginosa and A. baumannii. Gram-positive bacteria, Burkholderia cepacia, Serratia marcescens, Moraxella catarrhalis, Proteus spp., Providencia spp., and Morganella morganii are inherently resistant to colistin.7 Nephrotoxicity and neurotoxicity are the main adverse effects of colistin treatment. Despite these shortcomings, IV colistin has been used as salvage therapy in the treatment of pneumonia caused by MDR or COS gram negative pathogens due to the absence of effective alternative options.8

There are several studies evaluating the use of nebulized colistin either as monotherapy or as combination with systemic antibiotics for the treatment of pneumonia associated with MDR pathogens (Table 4). In some case-series studies, colistin inhalation adjunctive to IV colistin therapy has shown high favorable clinical and microbiological responses.9-12 However, the results from studies including control groups are not consistent. Korbila, et al.13 demonstrated that the outcome of ventilator-associated pneumonia was better in patients who received colistin inhalation with IV colistin than those who received IV colistin alone. By contrast, other studies showed that addition of aerosolized colistin to IV colistin resulted in no additional benefit.5,13 Aerosolized colistin inhalation with systemic antibiotics other than colistin also showed favorable clinical (61-100%) and microbiologic responses (60.9-83.3%).3,15-22 These studies include different combinations of concurrent antimicrobial regimen; therefore, the optimal combination and dosage should be determined by further studies. Colistin inhalation monotherapy without concurrent IV antimicrobial is rarely reported. In a case-series by Falagas, et al.21 two children received inhaled colistin monotherapy for tracheobronchitis and both cases showed a favorable response.

In our study, 8 patients who were treated with concurrent systemic antibiotics other than colistin, showed 100% clinical response, which was similar to the results from previous studies.3,15-22 However, colistin inhalation as monotherapy in our study showed only a 50% clinical response.

Four patients were treated with an inhaled colistin only, and the other 3 patients received concomitant IV antimicrobial, which has no gram negative activity. Understanding why physicians treated their patients with a colistin inhalation monotherapy is of interest. First, all of these patients were older and had neurovascular diseases. Accordingly, the physicians might be worried about neurotoxicity associated with systemic administration of colistin. The second reason is possible concern for nephrotoxicity. All the patients had hypoalbuminemia (2.4-2.8 g/dL) and two patients (Case 4 and 12) received IV vancomycin concurrently. The other 2 patients (Case 5 and 7) showed impaired renal function at that time. The third reason is likely financial. Except for co-infection by COS A. baumannii and colistin-resistant bacteria, The Korean National Health Insurance system often refuses reimbursement for colistin combination therapy with other antimicrobial agent having gram negative activity.
Inhaled Colistin Therapy for A. baumannii Pneumonia

Two major risks are arising from the wide use of colistin: the emergence of colistin resistance and an increase of infections due to gram-positive and gram-negative bacteria that are inherently resistant to colistin. With respect to resistance, colistin heteroresistance and colistin resistance in A. baumannii have been reported in several studies. In Korea, colistin resistance in A. baumannii was reported as 9.1% and 30.6%, respectively, in two different reports. In our hospital, colistin resistance rate in A. baumannii has been less than 1%. Although some studies suggested that nebulized antibiotic decreases bacterial resistance, colistin inhalation monotherapy may be problematic for treatment of infections due to gram-negative and gram-positive bacteria that are inherently resistant to colistin.

Table 4. Summary of Previous Studies on Colistin Inhalation Therapy for Pneumonia

| Authors/yr | Number of patients | Susceptibility and pathogen | Route of administration and other antibiotics | Colistin inhalation dose | APACHE II score | Duration of therapy | Therapeutic response (%) | Nephrotoxicity (%) |
|------------|--------------------|-----------------------------|-----------------------------------------------|-------------------------|----------------|-------------------|------------------------|------------------|
| Hamer, 2000 | 3 | MD R P. aeruginosa INH+other antibiotics | 150/100/140 mg q12 h | NA | 11-14 | 100 | 0 |
| Michalopoulos, et al. 2005 | 8 | COS/MDR A. baumannii INH+IV | 0.5-2 million IU q8 h | 14.6 | 10.5 | 87.5 | 0 |
| Motaouakkil, et al. 2006 | 16 | MDR A. baumannii INH+IV rifampicin | 1 million IU q8 h | 4-15 | 15 | 100 | 0 |
| Falagas, et al. 2006 | 9 | COS GNB INH+IV | 1 million IU q12 h | NA | 13 | 85 | 7 |
| Pereira, et al. 2007 | 14 | MDR GNB INH+IV or other antibiotics | 0.5 million IU q12 h | NA | 14 (4-25) | 93 | NA |
| Michalopoulos, et al. 2008 | 60 | MDR GNB INH+other antibiotics | 1 million IU q8 h | 16.7 | 16.4 | Microbiologic 83.3, clinical 83.3 | NA |
| Mastoraki, et al. 2008 | 8 | COS P. aeruginosa INH+IV | 0.5 million IU q8 h | NA | 15.9 | 70 | NA |
| Falagas, et al. 2009 | 5 | COS/MDR P. aeruginosa, A. baumannii INH+other antibiotics | 0.5-1 million IU q8 h | 11-27 | 6-11 | 80 | 0 |
| Korbila, et al. 2010 | 78 | MDR GNB INH+IV | 1 million IU q24 h | 17.4 | 79.5 | NA |
| Rattanaumpawan, et al. 2010 | 51 | GNB INH+other antibiotics | 75 mg q12 h | 19.1 | 12 | Microbiologic 60.9, clinical 51 | 25.5 |
| Kofleridis, et al. 2010 | 43 | MDR GNB INH+IV | 1 million IU q12 h | 16.95 | 13 (5-56) | Microbiologic 45, clinical 75 | 19 |
| Lin, et al. 2010 | 45 | MDR A. baumannii INH+IV or carbapenem | 2 million IU q8-24 h | 22.5 | 34 | Microbiologic 37.8, clinical 57.8 | 0 |
| Falagas, et al. 2010 | 3 | A. baumannii, P. aeruginosa INH+other antibiotics | 75 mg q12 h | NA | 25/32/15 | 100 | 0 |
| Nausens, et al. 2011 | 6/9 | MDR P. aeruginosa INH+other antibiotics | 2 million IU q8 h | NA | 27.2/19.3 | 100/78 | 0/20 |
| Nakwan, et al. 2011 | 8 neonates | COS A. baumannii INH+other antibiotics | 4 mg/kg q12 h | NA | 4-14 | 100 | NA |
| Kalin, et al. 2012 | 29 | MDR A. baumannii INH+IV | 75 mg q12 h | 22 | 14 | Microbiologic 76, clinical 14 | 41 |
| Celik, et al. 2012 | 3 neonates | MDR A. baumannii, P. aeruginosa INH+other antibiotics | 5 mg/kg q12 h | NA | 14/14/16 | 100 | 0 |

MDR, multidrug-resistant; GNB, gram negative bacilli; COS, colistin-only sensitive; NA, not available; INH, colistin inhalation therapy; IV, intravenous colistin therapy; APACHE, acute physiologic and chronic health evaluation.
pneumonia caused by colistin heteroresistant *A. baumannii*. To prevent the appearance of colistin resistance and to improve treatment efficacy, the optimization of the colistin dose is essential. Although previous studies with inhaled colistin therapy did not report any colistin-resistant isolates in patients with persistent isolation of *A. baumannii* or *P. aeruginosa*, our study results support this concern in that 3 patients showed resistance to colistin in subsequent sputum culture isolates within 20 days of colistin inhalation. The side effects of nebulized colistin include bronchoconstriction, cough, chest tightness, and apnea due to neuromuscular blockade. In this report, no patients were seen developing such adverse events. Our experience suggests that aerosolized colistin for pneumonia due to COS *A. baumannii* may offer advantages over systemic administration in respect to the occurrence of side effects. Theoretically, the use of the aerosolized colistin can minimize potential renal and neurologic toxicities because of negligible systemic absorption. A pharmacokinetic study of aerosolized colistin in cystic fibrosis patients revealed that the maximum observed serum colistin concentration was 0.178 mg/L, <10% of the level in sputum, and much less than the maximal level of 2.8-13.9 mg/L achieved by the IV route and this was undetectable 12 hours after the inhalation. We did not measure the plasma level of colistin in our patients, but it is reasonable to assume low-sodium levels and therefore a lower risk of systemic side effects in our patients. In our cases, nephrotoxicity was higher than previous studies. This seems to be due to the severity of patients’ diseases and concurrently administered glycopeptides. In addition, our definition of nephrotoxicity was more sensitive than in previous studies. Although the serum concentration is low, the possibility of systemic accumulation by repeated nebulization cannot be excluded. This could result in an increased risk for the selection of colistin resistant strains of *A. baumannii*.

Our study has some limitations. First, it was adapted from a single center, and a small case series were enrolled using a retrospective design. In addition, there we had no control group to compare our results. Second, neurotoxicity may not have been detected in our patients because most of them had underlying neurovascular diseases. Third, we identified Acinetobacter species by phenotypic method only; therefore, it is possible that non-*baumannii* species were included. Fourth, there is the possibility of isolated *A. baumannii* was not the etiology of pneumonia but colonization.

In summary, it is difficult to decide whether to use inhaled colistin monotherapy in pneumonia caused by COS *A. baumannii*. Moreover, superinfection with inherently colistin-resistant pathogens and the development of colistin resistant *P. aeruginosa* or *A. baumannii* should be prospectively monitored. The appropriate dose of aerosolized colistin, effective combination with other antimicrobial agents, and adequate indications remains to be determined in order to minimize these risks. A larger prospective and controlled study is needed.

### REFERENCES

1. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 2010;138:1333-9.
2. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006;57:306-11.
3. Rattanaumpawan P, Lorsuthitham J, Ungprasert P, Angkasekwinai N, Thamlilikul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010;65:2645-9.
4. Horan TC, Andrus M, Dudek MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32.
5. Kofleridis DP, Alexeopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulou D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010;51:1238-44.
6. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48:1724-8.
7. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183-90.
8. Levin AS. Treatment of Acinetobacter spp infections. Expert Opin Pharmacother 2003;4:1289-96.
9. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9.
10. Falagas ME, Kasiakou SK, Kofleridis DP, Rotitakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006;25:596-9.
11. Mastoraki A, Douka E, Kriaras I, Stravopodis G, Manoli H, Geroulanos S. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients. Surg Infect (Larchmt) 2008;9:153-60.
12. Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii
pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 2010;43:323-31.

13. Korbita IP, Michalopoulos A, Rafailidis PI, Nikitia D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010;16:1230-6.

14. Kalin G, Alp E, Coskun R, Demiraslan H, Gündogar K, Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother 2012;18:872-7.

15. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000;162:328-30.

16. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006;53:274-8.

17. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007;58:235-40.

18. Michalopoulos A, Fotakis D, Vritzlis V, Vletsas C, Rafailopoulou S, Mastora Z, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008;102:407-12.

19. Falagas ME, Siempos II, Rafailidis PI, Korbita IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Respir Med 2009;103:707-13.

20. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Leven M. A retrospective observational study on the efficacy of colistin by inhalation as compared to parental administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 2011;11:317.

21. Nakwan N, Wannaro J, Thongmak T, Pornladnum P, Saksawad R, Nakwan N, et al. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report. Pediatr Pulmonol 2011;46:60-6.

22. Celik IH, Ozgu SS, Demirel G, Erdeve O, Dilmen U. Outcome of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa treated with aerosolized colistin in neonates: a retrospective chart review. Eur J Pediatr 2012;171:311-6.

23. Falagas ME, Sideri G, Korbita IP, Vouloumanou EK, Papadatos JH, Kafetzis DA. Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. Pediatr Pulmonol 2010;45:1135-40.

24. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008;36:807-11.

25. Taccone FS, Rodriguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL, et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006;25:257-60.

26. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murphy AR, Jacobs MR, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009;53:3628-34.

27. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;59:473-7.

28. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2008;50:2946-50.

29. Herrera ME, Mobilia LN, Posse GR. [Comparative evaluation of the sensitivity of Acinetobacter to colistin, using the prediffusion and minimum inhibitory concentration methods: detection of heteroresistant isolates]. Rev Argent Microbiol 2011;43:115-9.

30. Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Fumiglia A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 2009;65:188-91.

31. Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge JD, Yu HH, et al. Colistin heteroresistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 2009;58:138-44.

32. Sung H, Choi SJ, Yoo S, Kim MN. [In vitro antimicrobial synergy against imipenem-resistant Acinetobacter baumannii]. Korean J Lab Med 2007;27:111-7.

33. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007;60:1163-7.

34. Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby J, et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;184:106-15.

35. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monte-forte M, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008;36:2008-13.

36. Michalopoulos A, Papadakis E. Inhaled anti-infective agents: emphasis on colistin. Infection 2010;38:81-8.